Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
Bone Remodeling01:40

Bone Remodeling

40.1K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.1K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.8K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

3.6K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.6K
What is the Skeletal System?01:02

What is the Skeletal System?

56.4K
Overview
56.4K
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

4.8K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Insulin therapy improves bone microstructure and material properties without restoring whole-bone strength in male insulin-deficient Akita mice.

Bone·2026
Same author

The gut-bone axis: microbial metabolism and nutritional interventions for bone health.

Gut microbes·2026
Same author

Consensus statement on the application of artificial intelligence in osteoporosis screening and management: perspectives from the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Orthogeriatric Fracture Syndrome: A Large-Scale Bibliometric Analysis of a Proposed Concept for Cross-Disciplinary Awareness and Coordinated Care.

Journal of clinical medicine·2026
Same author

Precision and age-related changes of 3D-DXA reconstructions and FEA of the proximal femur in comparison to DXA.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Dec 30, 2025

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

949

[Osteoporosis].

Emmanuel Biver1, Serge Ferrari1

  • 1Service des maladies osseuses, Département de médecine, HUG et Faculté de médecine, 1205 Genève.

Revue Medicale Suisse
|January 22, 2020
PubMed
Summary
This summary is machine-generated.

Osteoporosis treatment duration may exceed 5 years. Achieving a T-score of -1.5 to -2.0 may allow treatment discontinuation. Monitoring bone turnover markers is crucial after stopping certain osteoporosis medications.

More Related Videos

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.2K

Related Experiment Videos

Last Updated: Dec 30, 2025

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

949
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.2K

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Current osteoporosis treatment guidelines often recommend a 3- to 5-year duration, particularly for bisphosphonates.
  • The optimal duration and discontinuation criteria for newer anti-osteoporotic therapies require further clarification.
  • Bone remodeling dynamics and potential rebound effects after treatment cessation necessitate careful monitoring.

Purpose of the Study:

  • To evaluate the optimal bone mineral density (BMD) target for discontinuing osteoporosis treatment.
  • To assess the risk of bone remodeling rebound after denosumab discontinuation, even with concurrent zoledronate therapy.
  • To examine the efficacy of sequential therapy with romosozumab followed by denosumab in reducing fractures and increasing BMD.

Main Methods:

  • Analysis of treatment duration guidelines for various anti-osteoporotic agents.
  • Investigation of BMD targets (T-score) for treatment cessation.
  • Monitoring of C-terminal telopeptide (CTX) levels in patients undergoing sequential therapy or after denosumab discontinuation.
  • Evaluation of a sequential treatment regimen involving romosozumab and denosumab.

Main Results:

  • A T-score between -1.5 and -2.0 may serve as a target BMD for considering treatment discontinuation.
  • Bone remodeling rebound can occur post-denosumab discontinuation, even with zoledronate, highlighting the need for CTX monitoring.
  • Sequential therapy with one year of romosozumab followed by two years of denosumab significantly reduced vertebral and non-vertebral fractures.
  • This sequential treatment led to rapid and substantial gains in BMD within three years.

Conclusions:

  • Anti-osteoporotic treatment duration is not universally limited to 3-5 years, except for bisphosphonates.
  • BMD targets, specifically T-scores between -1.5 and -2.0, may guide treatment discontinuation decisions.
  • Close monitoring of bone turnover markers like CTX is essential after discontinuing certain osteoporosis medications, such as denosumab, due to potential rebound.
  • Sequential therapy combining romosozumab and denosumab offers a promising strategy for significant fracture reduction and BMD improvement in osteoporosis management.